Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 7Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 62Breast 41Sarcoma 25Gastrointestinal 18Other hematologic neoplasm 17Plasma cell 8CNS 6Thoracic 4Gynecologic 4Other solid neoplasm 3Genitourinary 3Myeloid 2Dermatologic 2Tumor-Agnostic 1

Conditions

Neoplasms, Unknown Primary 1

Interventions

Radiotherapy 9Drug Therapy 9Cisplatin 9Gemcitabine 8Docetaxel 7Carboplatin 7Blood Specimen Collection 7Nivolumab 6Fluorouracil 6Pemetrexed 5Capecitabine 5pembrolizumab 4Surveys and Questionnaires 4Positron Emission Tomography Computed Tomography 4Paclitaxel 4Oxaliplatin 4Exercise 4Everolimus 4Data Collection 4Cetuximab 4indibulin 3icotinib 3Vincristine 3Trastuzumab 3Standard of Care 3Radiosurgery 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Doxorubicin × Tumor-Agnostic × Clear all
NCT00022178 2013-09-20

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

National Cancer Institute (NCI)

Phase 3 Unknown
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡